SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-24-076566
Filing Date
2024-03-25
Accepted
2024-03-25 16:43:49
Documents
2
Group Members
VERSANT VANTAGE II GP, L.P.VERSANT VANTAGE II GP-GP, LLCVERSANT VANTAGE II, L.P.VERSANT VENTURE CAPITAL VII, L.P.VERSANT VENTURES VI GP, L.PVERSANT VENTURES VI GP-GP, LLCVERSANT VENTURES VII GP, L.P.VERSANT VENTURES VII GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d810139dsc13da.htm SC 13D/A 169399
2 EX-99.11 d810139dex9911.htm EX-99.11 10988
  Complete submission text file 0001193125-24-076566.txt   182537
Mailing Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Subject) CIK: 0001815776 (see all company filings)

IRS No.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92660 | Film No.: 24779854
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)